This is a working overview of HGF/c-Met, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-17 and is reviewed periodically as new material appears.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
==== MeSH E05.393.760 – sequence analysis ==== MeSH E05.393.760.640 – oligonucleotide array sequence analysis MeSH E05.393.760.700 – sequence analysis, dna MeSH E05.393.760.700.300 – dna mutational analysis MeSH E05.393.760.705 – sequence analysis, protein MeSH E05.393.760.705.685 – peptide mapping MeSH E05.393.760.705.685.690 – protein footprinting MeSH E05.393.760.710 – sequence analysis, rna
== Background == The monoisotopic mass is not used frequently in fields outside of mass spectrometry because other fields cannot distinguish molecules of different isotopic composition. For this reason, mostly the average molecular mass or even more commonly the molar mass is used. For most purposes such as weighing out bulk chemicals only the molar mass is relevant since what one is weighing is a statistical distribution of varying isotopic compositions. This concept is most helpful in mass spectrometry because individual molecules (or atoms, as in ICP-MS) are measured, and not their statistical average as a whole. Since mass spectrometry is often used for quantifying trace-level compounds, maximizing the sensitivity of the analysis is usually desired. By choosing to look for the most abundant isotopic version of a molecule, the analysis is likely to be most sensitive, which enables even smaller amounts of the target compounds to be quantified. Therefore, the concept is very useful to analysts looking for trace-level residues of organic molecules, such as pesticide residue in foods and agricultural products. Isotopic masses can play an important role in physics, but physics less often deals with molecules. Molecules differing by an isotope are sometimes distinguished from one another in molecular spectroscopy or related fields; however, it is usually a single isotope change on a larger molecule that can be observed rather than the isotopic composition of an entire molecule.
=== Mechanism of action === Disruption of the DNA structure caused by the crosslinksobstructs the DNA polymerases, preventing DNA replication and transcription. This causes the cell to go into cell cycle arrest it cannot go on from the G2 to the M phase and stops at the G2/M checkpoint. The cell tries to repair the DNA before dividing. The intrastrand crosslinks are normally repaired by the excision repair pathway. It attempts to remove the platinum adducts. If repair fails or is insufficient, apoptosis is induced and leads to cell death. However, cancer cells have impaired apoptosis pathways limited DNA repair pathways. This can decrease the efficacy of the drug and can lead to resistance to the drug. It has been observed that radiotherapy pairs well with administration with the drug, but how this works is not entirely established. It is known that cells that cells that are stuck at the G2/M phase of the cell cycle and have impaired DNA repair system are more sensitive to radiotherapy. This suggests that nedaplatin is a radiosensitizer,
=== April === 1 April Biochemists report finishing the complete sequence of the human genome. A study shows that, contrary to widespread belief, body sizes of mammal extinction survivors of the dinosaur-times extinction event were the first to evolutionarily increase, with brain sizes increasing later in the Eocene. 4 April The Intergovernmental Panel on Climate Change (IPCC) releases the third and final part of its Sixth Assessment Report on climate change, warning that greenhouse gas emissions must peak before 2025 at the latest and decline 43% by 2030, in order to likely limit global warming to 1.5 °C (2.7 °F). Researchers announce a new technique for accelerating the development of vaccines and other pharmaceutical products by up to a million times, using much smaller quantities based on DNA nanotechnology. Alzheimer's disease (AD) research progress:A study reports 42 new genes linked to an increased risk of AD. Researchers report a potential primary mechanism of sleep disturbance as an early-stage effect of neurodegenerative diseases. Researchers identify several genes associated with changes in brain structure over lifetime and potential AD therapy-targets (5 Apr).
It is hypothesized to function by changing its lowest luminescent state from n–π* to π–π* when coordinating to a metal. When the Dansyl group DNS binds to a metal, it loses a sulfonamide hydrogen, causing fluorescence quenching via a PET or reverse PET mechanism in which an electron is transferred either to or from the metal that is bound. Small molecule sensors for zinc have been reported. One example is "ZX1", a compound comprising a dipicolylamine (DPA) Zinc binding subunit that has greater affinity for Zinc than other species found in solution such as Ca and Mg. GFZnP OMe is an alternate, GFP-based fluorescent Zn2+ sensor is published for two-photon microscopy and related biological and microscop application. It composed of an 8-methoxyquinoline scaffold. It has excellent photophysical characteristics including a 37-fold fluorescence enhancement with l(ex) = 440 nm and l(em) = 505 nm. The two-photon cross-section is as high as 73 GM at 880 nm. GFZnP BIPY features a 2,2'-bipyridine chelator moiety. It was effective at physiologically relevant pH-range and excellent photophysical characteristics are reported, including a 53-fold fluorescence enhancement with excitation and emission maxima at 422 nm and 492 nm, respectively. High two-photon cross-section of 3.0 GM at 840 nm as well as excellent metal ion selectivity are reported. In vitro experiments on HEK 293 cell culture were carried out using two-photon microscopy demonstrating the applicability.
Sources: en.wikipedia.org
== Men on the Moon, space stations, space shuttles (1969–1991) == The latter period of the space race began with the United States landing the first men on the Moon, and was followed by the Soviets operating the first space stations and putting the first robotic landers on Venus and Mars, the US space shuttles marking the first significant reusable space vehicles, and a cooling down of tensions with the first docking between a Soviet and American vessel.
Crystal induced arthritis (gout, and pseudogout) – usually involves particular joints (knee, MTP1, heels) and can be distinguished with an aspiration of joint fluid if in doubt. Redness, asymmetric distribution of affected joints, pain occurs at night, and the starting pain lasts for less than an hour, with gout. Osteoarthritis – distinguished with X-rays of the affected joints and blood tests, older age, starting pain less than an hour, asymmetric distribution of affected joints, and pain worsens when using the joint for longer periods. Systemic lupus erythematosus (SLE) – distinguished by specific clinical symptoms and blood tests (antibodies against double-stranded DNA) One of the several types of psoriatic arthritis resembles RA – nail changes and skin symptoms distinguish between them Lyme disease causes erosive arthritis and may closely resemble RA – it may be distinguished by a blood test in endemic areas Reactive arthritis – asymmetrically involves heel, sacroiliac joints and large joints of the leg. It is usually associated with urethritis, conjunctivitis, iritis, painless buccal ulcers, and keratoderma blennorrhagica. Axial spondyloarthritis (including ankylosing spondylitis) – this involves the spine, although an RA-like symmetrical small-joint polyarthritis may occur in the context of this condition. Hepatitis C – RA-like symmetrical small-joint polyarthritis may occur in the context of this condition. Hepatitis C may also induce rheumatoid factor auto-antibodies. Rarer causes which usually behave differently but may cause joint pains:
Melamine Materials Safety Data Sheet (MSDS) OECD Screening Information Data Set (SIDS): Melamine (High Production Volume Chemicals Screening Information，PDF, 89 pages). FDA Web Page with Information on Pet Food Recall (due to Melamine contamination) European Commission decision (2008/798/EC) imposing special conditions governing the import of products containing milk or milk products originating from China Statement on melamine from the International Fertilizer Industry Association Toxicological and Health Aspects of Melamine and Cyanuric Acid: Report of a WHO Expert Meeting In collaboration with FAO Melmac Central's History on Melamine .
== Prognostic potential in cancer == Elevated MALAT1 expression is correlated with poor overall survival in various types of cancer, suggesting that this gene is a prognostic factor for different types of cancer. MALAT1 is implicated in multiple hallmarks of cancer, influencing cell proliferation, migration, angiogenesis, evasion of apoptosis, epithelial–mesenchymal transition, and cancer stem cell behavior. It exerts these effects through diverse mechanisms, including regulation of RNA splicing, modification of chromatin states, sponging of microRNAs, and remodeling of protein interactions, thereby modulating major oncogenic pathways such as PI3K/AKT, Wnt/β-catenin, TGF-β/Smad, mTOR, and Hippo–YAP signaling. MALAT1 also shapes the tumor immune microenvironment, contributing to immune evasion, therapy resistance, metabolic reprogramming, and exosome-mediated tumor–stromal communication. Although predominantly oncogenic, it can act as a tumor suppressor in a context-dependent manner.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.